Skip to main content

Universe Pharmaceuticals INC

corporate_fare Company Profile

Universe Pharmaceuticals INC

UPC·NASDAQ·Life Sciences·CIK 0001809616

Universe Pharmaceuticals INC manufactures, markets, distributes, and sells traditional Chinese medicine derivative products in China. The company's products address common chronic health conditions in the elderly, focusing on physical wellness and longevity, and also include cold and flu medications. Key products include guben yanling, shenrong weisheng, and quanlu pill; yangxue danggui and qiangli pipa syrup; wuzi yanzong oral, fengtong medicinal, shenrong medicinal, qishe medicinal, fengshitong medicinal, and shiquan dabu medicinal liquor; paracetamol granule for children; and isatis root granule. Additionally, Universe Pharmaceuticals INC distributes and sells third-party products such as biomedical drugs, medical instruments, traditional Chinese medicine pieces, and dietary supplements. The company serves pharmaceutical companies, hospitals, clinics, and drugstore chains. Founded in 1998, Universe Pharmaceuticals INC is headquartered in Ji'An, China, and operates as a subsidiary of Sununion Holding Group Limited.

Universe Pharmaceuticals INC (NASDAQ:UPC) is a publicly traded company in the Life Sciences sector. Wiseek monitors UPC SEC EDGAR filings and licensed market news in real time, scoring each submission for market-moving significance on a 1–10 scale. Items rated 7 or higher generate instant alerts.

Recent high-impact activity:

  • CEO Gang Lai Discloses 13.58% Beneficial Ownership in Universe Pharmaceuticals
  • CEO Granted 84,500 Shares, Resulting in 15% Dilution and 75% Voting Control
  • Universe Pharmaceuticals Adopts Highly Dilutive 2026 Equity Incentive Plan
  • Universe Pharmaceuticals Implements Dual-Class Share Structure, Concentrating Control
  • Universe Pharmaceuticals Reports Continued Losses, Secures $40M in Dilutive Offerings, Implements Dual-Class Share Structure, and Discloses Material Weakness

Financial Snapshot

Fiscal year ended September 30, 2025
Revenue
$17.86B
Net Income
-$3.67B
Diluted EPS
-$8.06
Op. Cash Flow
-$5.05B
Free Cash Flow
-$5.32B
Gross Profit
$6.3B
Operating Income
-$2.92B
Cash & Equivalents
$33.59B
Total Debt
$2.11B
Debt / Equity
0.04×
Net Margin
-20.6%
Shares Outstanding
563.34K sh
Source: 20-F · filed 2026-01-29 · accession 0001213900-26-009000

Insider Transactions

UPC files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.

Browse all tickers starting with U →
$3.1 -0.15% today
52-week range · as of 2026-05-21 $2 – $11
Market cap
$1.83M
Volume
5.1K (0.1× avg)
3-mo avg 36.7K
Live data · 2026-06-14 03:52 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed UPC - Latest Insights

UPC
May 21, 2026, 4:15 PM EDT
Filing Type: SCHEDULE 13D
Importance Score:
8
CEO Gang Lai Discloses 13.58% Beneficial Ownership in Universe Pharmaceuticals
Price at Filing: $2.69
Real-time Price: $3.10 info
Change: +$0.410 (+15%) info
Market Cap: $1.825M info
Sentiment: Neutral
View Wiseek Article
UPC
May 14, 2026, 4:10 PM EDT
Filing Type: 6-K
Importance Score:
7
CEO Granted 84,500 Shares, Resulting in 15% Dilution and 75% Voting Control
Price at Filing: $2.68
Real-time Price: $3.10 info
Change: +$0.420 (+16%) info
Market Cap: $1.825M info
Sentiment: Negative
View Wiseek Article
UPC
Apr 16, 2026, 4:10 PM EDT
Filing Type: 6-K
Importance Score:
8
Universe Pharmaceuticals Adopts Highly Dilutive 2026 Equity Incentive Plan
Price at Filing: $3.25
Real-time Price: $3.10 info
Change: -$0.150 (-5%) info
Market Cap: $1.825M info
Sentiment: Negative
View Wiseek Article
UPC
Feb 11, 2026, 4:06 PM EST
Filing Type: 6-K
Importance Score:
7
Universe Pharmaceuticals Implements Dual-Class Share Structure, Concentrating Control
Price at Filing: $3.62
Real-time Price: $3.10 info
Change: -$0.520 (-14%) info
Market Cap: $1.825M info
Sentiment: Negative
View Wiseek Article
UPC
Jan 28, 2026, 7:34 PM EST
Filing Type: 20-F
Importance Score:
9
Universe Pharmaceuticals Reports Continued Losses, Secures $40M in Dilutive Offerings, Implements Dual-Class Share Structure, and Discloses Material Weakness
Price at Filing: $4.22
Real-time Price: $3.10 info
Change: -$1.12 (-27%) info
Market Cap: $1.825M info
Sentiment: Negative
View Wiseek Article